|
|
|
|
|
|
|
|
|
|
Medical News
open access article: ATR inhibitors as a synthetic lethal therapy for tumours deficient in ARID1A, Chris T. Williamson, Rowan Miller, Helen N. Pemberton, Samuel E. Jones, James Campbell, Asha Konde, Nicholas Badham, Rumana Rafiq, Rachel Brough, Aditi Gulati, Colm J. Ryan, Jeff Francis, Peter B. Vermulen, Andrew R. Reynolds, Philip M. Reaper, John R. Pollard, Alan Ashworth & Christopher J. Lord, Nature Communications, doi: 10.1038/ncomms13837, published online 13 December 2016.
Discussion
Our data suggest that ATRi could have potential as single-agent treatments for ARID1A defective cancers. The highly recurrent nature of ARID1A mutations in human cancer and the availability of clinical ATRi suggests that once Phase I clinical trials are complete, biomarker driven proof-of-concept trials could be instigated to assess this hypothesis. These trials could be conducted in cancer types where there is a high frequency of ARID1A mutations, such as OCCC.....
0 comments :
Post a Comment
Your comments?
Note: Only a member of this blog may post a comment.